Caribou Biosciences Stock Quote CRBU - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

3.85

Bid

3.85

Ask

3.91

Volume

1,713,613

3.78 Day's Range 4.03

3.44 52 Week Range 8.5899

Market Cap

349.517M

Previous Close

3.92

Open

3.90

Last Trade

3.91

Last Trade Time

Financial Volume

$ 6,661,992

VWAP

3.8877

Average Volume (3m)

1,643,156

Shares Outstanding

90,314,501

Dividend Yield

PE Ratio

-3.42

Earnings Per Share (EPS)

-1.13

Revenue

34.48M

Net Profit

-102.07M

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.cariboubio.com

Headquarters

Dover, Delaware, USA

Founded

1970

Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $3.92. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 3.44 to $ 8.5899.

Caribou Biosciences currently has 90,314,501 shares outstanding. The market capitalization of Caribou Biosciences is $349.52 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -3.42.

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.52	-11.8993135011	4.37	4.3899	3.78	1623739	4.02750184	CS
4	-1.41	-26.8060836502	5.26	5.615	3.78	1619474	4.55320907	CS
12	-1.6	-29.3577981651	5.45	8.33	3.78	1643156	5.80207208	CS
26	-0.23	-5.63725490196	4.08	8.33	3.44	1690208	5.44159238	CS
52	-0.5	-11.4942528736	4.35	8.5899	3.44	1921822	5.68423883	CS
156	-13.8	-78.1869688385	17.65	32.645	3.44	1109882	8.06270886	CS
260	-13.8	-78.1869688385	17.65	32.645	3.44	1109882	8.06270886	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TWGTop Wealth Group Holding Ltd	$ 3.73 (101.62%)	36.52M
CSLRComplete Solaria Inc	$ 0.465319 (75.59%)	16.64M
SHOTWSafety Shot Inc	$ 0.48 (60.00%)	6.71k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
MNDRMobile health Network Solutions	$ 27.2386 (33.72%)	10.35M
YYAIConnexa Sports Technologies Inc	$ 0.8943 (-57.21%)	13.4M
SBFMSunshine Biopharma Inc	$ 1.77 (-46.69%)	11.9M
GTIGraphjet Technology	$ 6.43 (-33.09%)	95.33k
ISPCiSpecimen Inc	$ 0.2883 (-31.52%)	2.86M
BGLCBioNexus Gene Lab Corporation	$ 0.5998 (-29.32%)	735.88k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
SQQQProShares UltraPro Short QQQ	$ 12.84 (6.38%)	219.91M
AGBAAGBA Group Holding Ltd	$ 1.255 (21.84%)	128.79M
TQQQProShares UltraPro QQQ	$ 49.48 (-6.20%)	125.4M
SINTSiNtx Technologies Inc	$ 0.0414 (3.50%)	109.94M